Search
for
Sort by
Research 271–300 of 921
- Efficacy and safety of deuruxolitinib, an oral selective Janus kinase inhibitor, in adults with alopecia areata: Results from the Phase 3 randomized, controlled trial (THRIVE-AA1)
- Scoping Review on the Use of Drugs Targeting JAK/STAT Pathway in Atopic Dermatitis, Vitiligo, and Alopecia Areata
- Role of janus kinase inhibitors in the treatment of alopecia areata
- Evaluating the Therapeutic Potential of Ritlecitinib for the Treatment of Alopecia Areata
- A Comprehensive Literature Review of JAK Inhibitors in Treatment of Alopecia Areata
- The efficacy and safety of JAK inhibitors for alopecia areata: A systematic review and meta-analysis of prospective studies
- “‘You lose your hair, what’s the big deal?’ I was so embarrassed, I was so self-conscious, I was so depressed:” a qualitative interview study to understand the psychosocial burden of alopecia areata
- Treatments for alopecia areata: A systematic review and network meta‐analysis
- Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata over 52 Weeks of Continuous Therapy in Two Phase III Trials (BRAVE-AA1 and BRAVE-AA2)
- Alopecia in Children: The Most Common Causes
- Psychosocial and mental impact of alopecia areata: Analysis of the Danish Skin Cohort
- Dermoscopy of alopecia areata in restrospective analysis
- Patterns of clinical response in patients with alopecia areata treated with ritlecitinib in the ALLEGRO clinical development programme
- Nivolumab-Induced Alopecia Areata: A Case Report and Literature Review
- Factors influencing alopecia areata treatment decisions: A qualitative assessment
- Beyond health-related quality of life: initial psychometric validation of a new scale for addressing the gap in assessing the full range of alopecia areata psychosocial burden
- Janus kinase inhibitors for alopecia areata
- Using qualitative methods to establish the clinically meaningful threshold for treatment success in alopecia areata
- Baricitinib for the Treatment of Alopecia Areata
- Patterns of insurance coverage for wigs in patients with alopecia areata: a cross-sectional survey
- Alopecia areata
- Alopecia Associated With Zidovudine Therapy
- Efficacy and safety of deuruxolitinib, an oral selective Janus kinase 1/2 inhibitor, in adults with alopecia areata: Results from the THRIVE-AA2 Phase 3, randomized, double-blind, controlled trial
- Duration of current alopecia areata episode predicts the effectiveness of baricitinib in Japanese patients with alopecia areata: a single-center retrospective study
- Efficacy of Upadacitinib in Treating Alopecia Areata, Atopic Dermatitis, and Th1 Comorbidities in Pediatric Patients: A Comprehensive Case Series and Literature Review
- SALT score distribution with ritlecitinib treatment up to 24 months in alopecia areata
- Cytokine-Targeting Biologic Therapies for Alopecia Areata: A Comprehensive Review of Mechanism of Action, Clinical Efficacy, and Adverse Events
- 51840 Efficacy of the Oral JAK1/JAK2 Inhibitor Deuruxolitinib in Adult Patients with Moderate to Severe Alopecia Areata: Pooled Results from the Multinational Double-Blind, Placebo-Controlled THRIVE-AA1 and THRIVE-AA2 Phase 3 Trials
- Alopecia Areata of the Nails: Diagnosis and Management
- Janus kinase inhibitors for alopecia areata: A narrative review